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Abstract
Background: Tuberculosis (TB) of the central nervous system (CNS) is characterized by extensive tissue
inflammation, driven by molecules that cleave extracellular matrix such as matrix metalloproteinase (MMP)-1 and
MMP-3. However, relatively little is known about the regulation of these MMPs in the CNS.
Methods: Using a cellular model of CNS TB, we stimulated a human microglial cell line (CHME3) with conditioned
medium from Mycobacterium tuberculosis-infected primary human monocytes (CoMTb). MMP-1 and MMP-3
secretion was detected using ELISAs confirmed with casein zymography or western blotting. Key results of a
phospho-array profile that detects a wide range of kinase activity were confirmed with phospho-Western blotting.
Chemical inhibition (SB203580) of microglial cells allowed investigation of expression and secretion of MMP-1 and
MMP-3. Finally we used promoter reporter assays employing full length and MMP-3 promoter deletion constructs.
Student’s t-test was used for comparison of continuous variables and multiple intervention experiments were
compared by one-way ANOVA with Tukey’s correction for multiple pairwise comparisons.
Results: CoMTb up-regulated microglial MMP-1 and MMP-3 secretion in a dose- and time-dependent manner. The
phospho-array profiling showed that the major increase in kinase activity due to CoMTb stimulation was in p38
mitogen activated protein kinase (MAPK), principally the α and γ subunits. p38 phosphorylation was detected at 15
minutes, with a second peak of activity at 120 minutes. High basal extracellular signal-regulated kinase activity was
further increased by CoMTb. Secretion and expression of MMP-1 and MMP-3 were both p38 dependent. CoMTb
stimulation of full length and MMP-3 promoter deletion constructs demonstrated up-regulation of activity in the
wild type but a suppression site between -2183 and -1612 bp.
Conclusions: Monocyte-microglial network-dependent MMP-1 and MMP-3 gene expression and secretion are
dependent upon p38 MAPK in tuberculosis. p38 is therefore a potential target for adjuvant therapy in CNS TB.
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Background
Tuberculosis (TB) remains a deadly disease responsible
for approximately 1.5 million deaths a year, many caused
by disseminated disease involving the central nervous
system (CNS) [1]. During active disease, infection of
monocytic cells by Mycobacterium tuberculosis (M.tb) re-
sults in an intense host-driven inflammatory response
that contributes not only to pathogen death, but also to
local tissue destruction and immunopathology. In CNS
TB, this inflammatory reaction is not well-tolerated and
is responsible for infarction, hydrocephalus, neuronal
damage and death.
Monocytic cell-derived matrix metalloproteinases (M
MPs) are central mediators of TB-driven pulmonary
tissue destruction due to their ability to degrade fibrillar
collagens [2]. Indeed this family of 23 proteases with
differing, but overlapping, substrates can degrade all ele-
ments of the extracellular matrix at neutral pH, differen-
tiating them from other proteases that might also be
induced in inflammatory situations [3,4]. MMPs perform
multiple roles in development, reproduction and the
normal immune response, such as facilitating leucocyte
recruitment, processing cytokines and chemokines, acti-
vating defensins and remodelling matrix [5]. In the CNS,
MMPs are known to have a number of substrates, such
as dystroglycan, a transmembrane receptor that anchors
astrocyte endfeet to the basement membrane via laminin
binding [6]. Cleavage of these molecules contributes to
blood-brain barrier breakdown. The resident CNS innate
immune cell is the microglia, most likely of mesodermal
monocyte-lineage origin [7]. We and others have previ-
ously shown that microglia secrete high concentrations
of MMPs in CNS TB [8-10]. MMP-1, MMP-3, MMP-8
and MMP-9 are found at high concentrations in the
cerebral spinal fluid (CSF) of CNS TB patients [11]. In
addition, MMP-1, MMP-3 and -9, but not the specific
tissue inhibitor of metalloproteinase (TIMP) -1, are
present in CNS tuberculomas [9,12]. Specifically MMP-1
is an interstitial collagenase able to digest aggrecan and
collagen at neutral pH, and MMP-3 is a stromelysin with
substrates such as fibronectin, laminin and type IV colla-
gen [3]. Finally dexamethasone, a specific and proven
adjuvant to anti-tuberculous chemotherapy that im-
proves patient outcomes, specifically suppresses MMPs,
but not TIMPs, in CNS TB patients [11,13].
Intracellular signalling is critical to control of MMP
transcription and secretion. We have shown that nuclear
factor-κB (NF-κB) and activator protein (AP)-1 pathways
are activated both in vitro and in patients with CNS TB
[9]. Furthermore, the bacteriostatic TB drug para-amino-
salicyclic acid exerts its anti-TB activity in part due to in-
hibition of the prostaglandin pathway, thereby reducing
MMP-1 secretion and tissue destruction [14]. Upstream of
these signalling pathways are the mitogen-activated
protein kinases (MAPKs). The three main pathways are
p38, c-Jun N-terminal kinase (JNK) and extracellular
signal-regulated kinase (ERK)-1/2. The extracellular
signal-regulated MAPK are involved in cell turnover and
phosphorylation of transcription factors and microtubule-
associated proteins, whereas the p38 MAP kinase subfam-
ily regulates cell differentiation, apoptosis and cellular
response to inflammation. p38 MAPK may be an important
point of divergence in the regulation of MMP and TIMP
secretion in pulmonary TB [15]. In the CNS, MMP-9 secre-
tion by astrocytes was dependent upon an IL-1β/MAP
kinase/AP-1 pathway [16].
In this study, we tested the hypothesis that MAPK path-
ways are key factors in the control of microglial MMP
gene expression and secretion using a cellular model of
CNS TB. We present evidence that the p38 pathway is the
principle regulator of MMP secretion in microglia, causing
divergent secretion of MMP-1 and MMP-3 and their asso-
ciated TIMPs.
Methods
Reagents
Chemicals were from Sigma-Aldrich (Gillingham, UK),
tissue culture materials from Invitrogen (Paisley, UK)
and tissue culture plastic from TPP (Trasadingen,
Switzerland) unless otherwise stated. Inhibition experi-
ments were performed with a two-hour pre-incubation of
the specific p38 chemical inhibitor SB203580 from
Promega (Southampton, UK) at concentrations as shown.
M.tb culture
The virulent M.tb strain H73Rv Pasteur was cultured in
Middlebrook 7H9 broth (BD Biosciences, Oxford, UK)
with 10% OADC enrichment medium, 0.2% glycerol and
0.02% Tween 80 with agitation. M.tb at optical density
(OD) 0.6 (Biowave Cell Density Meter; WPA, Cambridge,
UK), corresponding to 108 colony forming units/ml (cfu/
ml) was used for infection. Endotoxin level was <0.03 ng/
ml lipopolysaccharide (LPS) (Amoebocyte lysate assay,
Associates of Cape Cod, Falmouth, MA, USA).
Cell culture and M.tb infection
Monocytes were isolated from healthy blood donors (UK
Blood Transfusion Service) by Ficoll-Paque (GE Health-
care, Little Chalfont, UK) density gradient centrifugation
and adherence purification [17]. Monocytes were infected
with M.tb at a multiplicity of infection of 1. At 24 hours,
cell culture medium was collected and 0.2 μm was sterile-
filtered (Nalgene, Hereford, UK) to remove infectious par-
ticles but not MMPs [18]. Conditioned medium from M.
tb-infected monocytes was termed CoMTb and control
medium from uninfected monocytes was CoMCont.
Human CHME3 microglial cells (used with permission
of Marc Tardieu, Paris, France and kindly provided by
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Nicola Woodroofe, Sheffield Hallam University, UK) were
maintained in DMEM with 10% FCS (Biosera, Ringmer,
UK) and 3 mM glutamine. Cells were seeded at 35,000 to
50,000 cells/cm2 for experiments, which were performed
in macrophage serum-free medium (MSFM).
RNA extraction, cDNA synthesis and quantitative reverse-
transcribed PCR (qRT-PCR)
Microglia were lysed with TRI reagent and total RNA was
extracted. cDNA was prepared from 1 ug RNA and re-
verser transcribed using 2 μl of random primers and
200 units SuperScript III reverse transcriptase (both
Invitrogen), according to supplier’s instructions. Quantita-
tive PCR (qPCR) was performed as previously described [9].
The cycle threshold (Ct) at which amplification entered the
exponential phase was determined and this number was
used to indicate the amount of target RNA in each sample.
MMP Cts were normalized to ribosomal 18S mRNA.
Casein zymography
We loaded 20 μl of cell culture medium with 5 μl of loa-
ding buffer (0.25 M Tris pH 6.8, 50% glycerol, 5% SDS
and bromophenol blue crystals) on 12% casein gels
(Invitrogen). Gels were run at 125 V for 2.5 hours (buffer
25 mM Tris, 190 mM glycine and 0.1% SDS). After one
hour incubation in 2.5% Triton-X, gels were transferred to
collagenase buffer (55 mM Tris base, 200 mM NaCl, 5
mM CaCl2 and 0.02% Brij; pH 7.6) for 40 hours at 37°C.
Gels were stained with 0.2% Coomassie blue (Pharmacia
Biotech, Sweden) for one hour before de-staining in acetic
acid/methanol/water (1:3:6), and 5 ng of MMP-1 standard
(Merck, Germany) was run on each gel. Gels were analyzed
densitometrically by Scion Image Analysis (NIH Image ver-
sion 1.61, Bethesda, MD, USA) normalized to standard.
Western blotting
Standard MMP-1 western blotting was performed as de-
scribed [19]. Overnight incubation in 1:1,000 MMP-1 pri-
mary antibody (The Binding Site, Birmingham, UK) in 5%
milk protein was followed by washing and incubation with
1:2000 peroxidase-conjugate secondary antibody for an
hour (The Binding Site). Bands were visualized by chemi-
luminescence with the ECL Plus system (GE Healthcare)
according to manufacturer’s instructions. MMP-3 western
blotting was performed using 1:5,000 rabbit anti-MMP-3
primary antibody (Chemicon, Millipore, Watford, UK) in
5% bovine serum albumin and 1:2,000 horseradish perox-
idase (HRP)-linked anti-rabbit secondary (Cell Signalling
Technology, Danvers, MA, US) in 5% milk protein. For
MAPK experiments, cells were lysed using 200 μl of SDS
sample buffer (62.5 mM Tris pH 6.8, 2% SDS, 10% gly-
cerol, 50 mM DTT and 0.01% bromophenol blue) and im-
mediately frozen at −80°C. Then, 40 μl aliquots were run
on western gels as described and probed with 1:1,000
rabbit primary antibodies to both phosphorylated and
unphosphorylated forms of p38 or ERK MAPK. 1:2,000 di-
lution of anti-rabbit HRP-linked secondary antibody was
used (all Cell Signalling Technology).
Luminex analysis
MMP-1 and MMP-3 concentrations were analyzed by
Fluorokine MAP profiling kit according to the manufac-
turer’s protocol (R&D systems) on the Luminex platform
(Biorad, Hemel Hempstead, UK). The minimum level of
detection for MMP-1 was 10 pg/ml and 15 pg/ml for
MMP-3.
MMP-3, TIMP-1 and -2 ELISAs
MMP-3 and TIMP-1 and TIMP-2 concentrations in cell
culture medium were measured by ELISA (R&D Systems)
according to the manufacturer’s instructions. The lower
limit of detection was 30 pg/ml.
Phospho-MAPK array
The Proteome Profiler phospho-array (R&D systems) was
used to investigate multiple kinase pathways. We stimu-
lated 106 microglia with CoMCont or CoMTb for 30 mi-
nutes. The phospho-array was performed according to the
manufacturer’s protocol and developed with the ECL sys-
tem (GE Healthcare). Densitometric analysis of each array
was performed using NIH Image version 1.61. The Prote-
ome Profiler kit measured relative MAPK and related
serine/threonine kinase phosphorylation status. Six positive
controls are incorporated onto the membrane. Mean inten-
sity was calculated for CoMCont and CoMTb. Data are
presented as the difference between these mean intensities.
Promoter reporter analysis
Microglial cells were co-transfected with MMP-3 pro-
moter constructs and a control reporter plasmid, cons-
titutively expressing Renilla luciferase, with Fugene HD
(Roche). Cells were stimulated after 18 hours, and lucifer-
ase activity analyzed 24 hours later by the Dual-Luciferase
Reporter Assay System (Promega) on a luminometer
(Medical Devices, Wokingham, UK). Renilla luciferase ac-
tivity was used to normalize firefly luciferase activity to
control for transfection efficiency.
Statistics
Data are presented as means (± SD) of three samples and
represent experiments performed in triplicate on at least
two occasions, unless otherwise stated. Paired groups were
compared with Student’s t-test. Multiple intervention ex-
periments were compared by one-way analysis of variance
(ANOVA) and Tukey’s correction for multiple pairwise
comparisons with equal variance tested by Levene’s test.
P <0.05 was taken as significant. All analysis was done using
SPSS software (version 15.0, SPSS corp., Chicago, IL, USA).
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Results
Monocyte-microglial networks drive MMP-1 and MMP-3
secretion from human microglia
Increasing concentrations of CoMTb but not CoMCont
resulted in greater secretion of MMP-1 and MMP-3 in a
dose-dependent manner (Figure 1A and B). Specifically,
MMP-1 secretion showed a stepwise increase in secretion
9.2-fold higher at the 1:10 dilution of CoMTb compared
to CoMCont and reaching 27.9-fold greater at 1:2 dilu-
tions (all P <0.01). MMP-3 secretion was 12-fold higher at
the 1:10 dilution of CoMTb than the equivalent CoMCont
concentration and 58-fold at the 1:2 dilution (P <0.01).
Since there was no further increase in MMP-3 secretion
after a 1:5 dilution of CoMTb, this concentration was
subsequently used to stimulate cells in all experiments.
MMP-1 and MMP-3 kinetic experiments demonstrated a
significant difference in MMP secretion in response to
CoMTb compared to CoMCont (Figure 1C and D).
MMP-1 activity was detectable at 24 hours and maximal
at 96 hours with a 5.3-fold change from CoMCont
(P <0.01). MMP-3 secretion peaked at 72 hours with a 58-
fold increase, but there was no further increase at 96
hours (P <0.01). Therefore, cell culture supernatants were
harvested at 72 hours in subsequent experiments.
Phospho-array analysis of CoMTb-stimulated microglia
Next, we investigated the intracellular signalling path-
ways regulating MMP-1/3 secretion using phosphor-array
screening. The ERK and AKT pathways were activated
in CoMCont-stimulated cells. At 30 minutes, CoMTb-
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Figure 1 Matix metalloproteinsase (MMP)-1 and MMP-3 secretion is up-regulated by conditioned media from tuberculosis (TB)-
infected monocytes (CoMTb) in a dose- and time-dependent fashion. (A and B) Microglial cells were stimulated with control medium (open
bars), or increasing concentrations of conditioned media from control monocytes (CoMCont) (diagonal hatched bars) and CoMTb (solid bars); 72-
hour supernatants were analyzed by Luminex for MMP-1 or MMP-3. A representative casein zymogram is also shown (A). Kinetics of MMP-1
activity (C) and MMP-3 secretion (D) demonstrate progressive increase in concentration for up to 72 hours. Bars represent mean values ± SD of
three samples, representative of at least duplicate experiments performed in triplicate. *P <0.05, **P <0.01.
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Figure 2 Conditioned media from tuberculosis (TB)-infected monocytes (CoMTb) drive phosphorylation of the extracellular signal-
regulated kinase (ERK), p38 and AKT mitogen-activated protein kinase (MAPK) pathways in microglial cells. (A) Proteome profiler array of
conditioned media from control monocytes (CoMCont)- and CoMTb-stimulated microglia at 30 minutes. CoMTb drives p38 activity and further
phosphorylation of constitutive ERK 1/2 and AKT activity. (B) Densitometric analysis of phospho-array. Densitometric analysis of differences in
mean spot intensity between CoMCont- and CoMTb-stimulated cells is presented, demonstrating that the p38α and p38γ subunits are the
principal CoMTb up-regulated MAP kinases. (C) p38 phosphorylation kinetics. CoMTb drives up-regulation of p38 at 15 minutes, with a second
peak at 120 minutes. (D) CoMCont-stimulated microglial ERK activity at 30 minutes shows high basal activity further up-regulated by CoMTb. Only
CoMTb activity was blocked by the inhibitor PD98059. Representative data from three independent experiments are shown. Bars represent mean
+/− standard error of the mean from three independent experiments. *P <0.05, **P <0.01.
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stimulated multiple signalling pathways including ERK,
p38, AKT, GSK, JNK and HSP-27 (Figure 2A). Densito-
metric analysis of differences in mean spot intensity be-
tween stimulated and unstimulated cells demonstrated that
ERK-1/2 and AKT phosphorylation were up-regulated to
the greatest extent in CoMTb-stimulated cells (Figure 2B).
The increases in different p38 isoforms were divergent.
CoMTb stimulated p38α phosphorylation 311% more than
CoMCont (P <0.05) and p38γ phosphorylation increased
by 154% (P <0.05). p38β and p38δ phosphorylation did not
change.
To investigate phospho-array findings further, kinetic
Western blot analysis of CoM-stimulated p38 phosphoryl-
ation in microglia was performed over 120 minutes
(Figure 2C). Minimal basal phosphorylation was seen.
CoMTb stimulated p38 phosphorylation at 15 minutes,
which waned by 60 minutes. However, a second peak
of phosphorylation was detected at 2 hours. At 30
minutes, basal ERK phosphorylation was detected.
Although CoMTb up-regulated ERK phosphorylation was
blocked by PD98059 in a dose-dependent manner, the basal
phosphorylation made subsequent interpretation of the
effect of ERK hard to interpret, and so it was not studied
further (Figure 2D).
Regulation of MMP-1 and MMP-3 secretion by p38
To dissect the role of the p38 pathway in control of
MMP-1 and MMP-3 secretion, a specific chemical inhibi-
tor (SB203580) was pre-incubated with microglia prior to
CoMTb stimulation. MMP-1 secretion was suppressed by
45.6% by 1 μM and 92% by 10 μM SB 203580 (P <0.05
and P <0.01 respectively) (Figure 3A). MMP-3 was also
p38-dependent; 1 and 10 μM SB203580 reduced MMP-3
secretion by 28.8% and 83.2% respectively (both P<0.01)
(Figure 3B).
MMP-1 and MMP-3 gene expression were investigated
by qRT-PCR. MMP-1 gene expression was up-regulated by
CoMTb (Figure 4A). This up-regulation was suppressed by
inhibition of the p38 MAPK. MMP-3 mRNA accumulation
was also decreased by p38 inhibition (Figure 4B), consist-
ent with secretion data.
25
50
75
Ca
se
in
ol
yt
ic
 
 
 
 
 
a
ct
iv
ity
CoMTb ++ +- -
SB203580 μM 1 10- - -
**
*
A)
MMP-1
MMP-1
**
CoMCont - - -+-
CoMTb ++ +- -
SB203580 μM 1 10- - -
40
30
20
10
M
M
P-
3 
ng
/m
l
MMP-3
**
**
B)
CoMCont - - -+-
Figure 3 p38 phosphorylation controls both matix
metalloproteinsase (MMP)-1 and MMP-3 secretion in
conditioned media from tuberculosis (TB)-infected monocytes
(CoMTb)-stimulated microglia. Microglial cells were incubated
with SB203580 for 2 hours, and then stimulated with CoMTb. (A)
MMP-1 activation and secretion was analyzed at 72 hours by casein
zymography (representative gel shown) and western blotting. (B)
MMP-3 activity was analyzed by ELISA and western blotting. p38
inhibition suppressed CoMTb MMP-1 and MMP-3 suppression in a
dose-dependent manner. Bars represent mean values ± SD of three
samples, representative of at least duplicate experiments performed
in triplicate. Data were analyzed by one-way analysis of variance,
followed by Tukey’s multiple comparison test. *P <0.05, **P <0.01.
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The MMP-3 promoter is up-regulated by CoMTb and has
a suppression site between −2183 and −1612 bp
The MMP-3 promoter has multiple transcription factor
binding sites (Figure 5A) and has not been previously in-
vestigated in CNS TB. MMP-3 promoter reporter analysis
demonstrated that CoMTb increased the 2183 bp full-
length promoter activity above CoMCont levels by 3.4-
fold at 24 hours (Figure 5B, P <0.05). A significant rise in
promoter activity was seen with the 1612 bp promoter
compared to the full length promoter in response to
CoMTb stimulation (P <0.01). Promoter activity was de-
creased compared to CoMCont levels when the shorter
642 bp construct was stimulated with CoMTb,
suggesting that this construct does not contain the mi-
nimal elements necessary to allow promoter activity in
response to CoMTb.
Discussion
In this study, we have demonstrated that MMP-1 and
MMP-3 secretion from monocyte-microglial networks are
dependent on the p38, MAPK pathway in a cellular model
of CNS TB. This control acts, at least in part, at the tran-
scriptional level. We also defined that a key repressor
element exists in the MMP-3 promoter upstream of
−1612 from the transcriptional start site.
First, we delineated that CoMTb, but not CoMCont,
drives dose-dependent MMP-1 and MMP-3 secretion.
This effect peaked for MMP-3 at 72 hours, but MMP-1
secretion increased until 96 hours. Next, using phosphor-
arrays, we demonstrated that the ERK and AKT pathways
were active in CoMCont-stimulated cells. These pathways
are responsible for cell turnover, and therefore, basal ex-
pression in cell lines is commonly found [20]. Second,
although there was increased phosphorylation of these
pathways with CoMTb, the p38 pathway, and in particular
the p38α and γ subunits, stood out as principle targets of
CoMTb-activated signaling. This was confirmed in kinetic
studies where biphasic phosphorylation of p38 was ob-
served. Biphasic p38 activation is linked to the apoptotic
pathway, which is activated only after the second peak in
phosphorylation [21]. No specific subunit analysis was
performed in our experiments, because the antibody used
recognizes epitopes common to all four p38 subunits.
However, M.tb has also been shown to directly drive p38
phosphorylation in microglia. Yang et al. demonstrated
that sonicated (therefore dead) M.tb stimulated p38 phos-
phorylation in a toll-like receptor (TLR)2-dependent man-
ner [22]. In our study, p38α activation was most marked.
Conditional knockout of p38α in murine macrophages dif-
ferentially affects bacterial phagocytosis and LPS-induced
TNF-α, but not IL-6, secretion via the attenuation of the
transcription factor cAMP response element-binding pro-
tein (CREB) but not the NF-κB pathway [23]. There is
emerging evidence that p38 inhibition may have a
therapeutic role in the treatment of cerebral ischaemia,
where it reduces neuronal death and microglial activation
suggesting a possible translational application for our data
[24]. In addition, we found that MMP-3 was solely p38-
dependent, and thus, p38 appears to be a central cellular
control point for MMP-1 and MMP-3 secretion in micro-
glial cells.
The high ERK basal phosphorylation up-regulated by
CoMTb observed in the MAP kinase array was confirmed
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Figure 4 Matrix metalloproteinase (MMP)-1 and MMP-3 gene
expression is suppressed by p38 inhibition. (A) Shows MMP-1
and (B) shows MMP-3 gene expression. mRNA from microglia
stimulated for 24 hours with conditioned media from tuberculosis
(TB)-infected monocytes (CoMTb) was analyzed by real-time PCR,
normalized to 18S RNA and expressed as fold-change relative to
mRNA from 24 hour-conditioned media from control monocytes
(CoMCont). The mean ± SD from three experiments are shown. Data
were analyzed by one-way analysis of variance, followed by Tukey’s
multiple comparison test. *P <0.05, **P <0.01.
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by western blotting. However, since in cell lines, high basal
ERK activity is driven by the immortalization process, we
chose not to study this pathway further. However, ERK ac-
tivation is known to contribute to the control of MMP se-
cretion in the CNS, macrophages and other cells,
suggesting a ubiquitous, rather than specific, cellular role
for this MAPK [16,25,26]. Specifically, further experiments
in primary cells are warranted to confirm these prelimin-
ary findings. Gene expression data exactly reflected secre-
tion data although the extent of any post-transcriptional
effect on MMP-1 regulated by p38 was not investigated in
the present study.
Finally promoter-reporter studies demonstrated CoMTb-
specific up-regulation of promoter activity, and also indi-
cated that a repressor element exists in the upstream part
of the promoter (−1612 to −2183). The exact repressor
element demonstrated to be acting here is as yet undefined.
Tantalizingly the 1612 bp construct exactly disrupts a previ-
ously reported SIRE binding site, a transcription factor as-
sociated with down-regulation of MMP-3 secretion in
fibroblasts [27]. In microglial cells, we have previously
proven that the observed CoMTb effect involves synergy
between TNF-α and IL-1β for MMP-3 but not MMP-1 se-
cretion, supporting the role of this latter cytokine [9]. How-
ever, unlike in respiratory epithelial cells and macrophages,
we have been unable to demonstrate an additional effect of
M. tb-derived antigens on secretion of MMPs or p38
MAPK signalling via TLR2, respectively, in this model sys-
tem [14,15].
Conclusions
We have demonstrated that in CNS TB, MMP-1 and
MMP-3 secretion from monocyte-microglial networks are
critically dependent upon the p38 MAP kinase pathway,
and this pathway may warrant further investigation as a
therapeutic target in CNS TB.
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t-test (**P <0.01).
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nervous system; CREB: cAMP response element-binding protein;
CSF: Cerebrospinal fluid; Ct: Cycle threshold; DMEM: Dulbecco’s modified Eagle’s
medium; ELISA: Enzyme-linked immunosorbent assay; ERK: Extracellular signal-
regulated mitogen-activated protein kinase; FCS: Fetal calf serum;
HRP: Horseradish peroxidase; IL: Interleukin; MAPK: Mitogen-activated protein
kinase; MMP: Matrix metalloproteinase; MSFM: Macrophage serum-free medium;
NF-Κb: Nuclear factor-κB; OD: Optical density; qPCR: Quantitative polymerase
chain reaction; SIRE: Stromelysin IL-1 responsive element; TB: Tuberculosis;
TIMP: Tissue inhibitor of metalloproteinase; TLR: Toll-like receptor; TNF: Tumour
necrosis factor.
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